Canalicular secretion of bile salts is a vital function of the vertebrate liver, yet the molecular identity of the involved ATP-dependent carrier protein has not been elucidated. We cloned the full-length cDNA of the sister of P-glycoprotein (spgp; M r ϳ160,000) of rat liver and demonstrated that it functions as an ATP-dependent bile salt transporter in cRNA injected Xenopus laevis oocytes and in vesicles isolated from transfected Sf9 cells. The latter demonstrated a 5-fold stimulation of ATP-dependent taurocholate transport as compared with controls. This spgp-mediated taurocholate transport was stimulated solely by ATP, was inhibited by vanadate, and exhibited saturability with increasing concentrations of taurocholate (K m Ӎ 5 M). Furthermore, spgp-mediated transport rates of various bile salts followed the same order of magnitude as ATP-dependent transport in canalicular rat liver plasma membrane vesicles, i.e. taurochenodeoxycholate > tauroursodeoxycholate ‫؍‬ taurocholate > glycocholate ‫؍‬ cholate. Tissue distribution assessed by Northern blotting revealed predominant, if not exclusive, expression of spgp in the liver, where it was further localized to the canalicular microvilli and to subcanalicular vesicles of the hepatocytes by in situ immunofluorescence and immunogold labeling studies. These results indicate that the sister of P-glycoprotein is the major canalicular bile salt export pump of mammalian liver.Bile formation is an important function of vertebrate liver (1). It is mediated by hepatocytes that generate bile flow within bile canaliculi by continuous vectorial secretion of bile salts and other solutes across their canalicular (apical) membrane (2). Studies in isolated membrane vesicles of rat and human livers have shown that canalicular bile salt transport is an ATP-dependent process (3-7). However, the molecular identity of the primary active canalicular bile salt transporter or bile salt export pump (BSEP) 1,2 has not yet been elucidated (8, 9). Although the canalicular ecto-ATPase has been proposed as a possible candidate (9, 10), other investigations have provided evidence that BSEP of mammalian liver is an ABC (ATP binding cassette)-type of membrane transporter (11,12). This assumption has recently been further supported by the cloning of an ATP-dependent bile salt transporter from Saccharomyces cerevisiae (13). This yeast bile salt transporter (BAT1) belongs to a subgroup of ABC-type proteins that includes also the canalicular multiorganic anion transporter or multidrug resistance protein MRP2 (human)/mrp2 (rat) (14 -16). Although MRP2/mrp2 mediates canalicular excretion of a broad range of divalent amphipathic anionic conjugates (1, 14, 17), it does not transport primary bile salts such as taurocholate or glycocholate (1, 18). Therefore, we designed degenerate oligonucleotide primers spanning the Walker A and B motifs of ABC proteins and performed reverse transcription-polymerase chain reactin with total rat liver mRNA. One of the amplified fragments revealed an 88% identity with the p...

No abstract

The multidrug resistance-associated proteins (Mrps) constitute a family of cellular export pumps of the ATP-binding cassette transporter superfamily and play an important role in hepatobiliary excretion. We investigated the transport function and subcellular localization of mrp6, a novel member of the mrp family, in rat liver. Transport studies in vesicles isolated from mrp6 expressing Sf9 cells identified the anionic cyclopentapeptide and endothelin receptor antagonist BQ-123 as a substrate of mrp6 (K(m) approximately 17 microM). Besides BQ-123, which is also a substrate of mrp2 (K(m) approximately 124 microM), no other common substrates were found for mrp2, mrp6, and the canalicular bile salt export pump Bsep. The cyclic peptides endothelin I and Arg(8)-vasopressin were transported by mrp2 but not by mrp6. Using a polyclonal antiserum raised against a C-terminal peptide, mrp6 was found to be localized at the lateral and, to a lesser extent, at the canalicular plasma membrane of hepatocytes. The limited overlap of the substrate specificity with the canalicular export pumps mrp2 and Bsep indicates that mrp6 does not play a major role in canalicular organic anion excretion. However, its dual localization at the lateral and canalicular plasma membrane suggests that mrp6 might fulfill a "housekeeping" transport function involved in the regulation of paracellular and/or transcellular solute movement from blood into bile.

Background Activated protein C (aPC) mediates powerful cytoprotective effects through protease activated receptor (PAR)-1 that translate into reduced harm in mouse injury models. However, it remains elusive how aPC-activated PAR1 can mediate cytoprotective effects while thrombin activation does the opposite. Objectives We hypothesized that aPC and thrombin might induce distinct active conformations in PAR1 causing opposing effects. Methods We analyzed antibody binding to, and cleavage and signalling of PAR1 in either endogenously expressing endothelial or overexpressing 293T cells. Results In thrombin-cleaved PAR1 neither the tethered ligand nor the hirudin like domain were available for anti-PAR1 ATAP2 and WEDE15 binding unless the tethered ligand was quenched. In contrast, aPC irreversibly prevented ATAP2 binding while not affecting WEDE15 binding. Reporter constructs with selective glutamine substitutions confirmed R41 as the only thrombin cleavage site in PAR1, whereas aPC preferentially cleaved at R46. Similarly, we report distinct cleavage sites on PAR3, K38 for thrombin and R41 for aPC. A soluble peptide corresponding to R46-cleaved PAR1 enhanced the endothelial barrier function and reduced staurosporine toxicity in endothelial as well as in 293T cells if PAR1 was expressed. Overexpression of PAR1 variants demonstrated that cleavage at R46 but not R41 is required for cytoprotective aPC signaling. Conclusions We provide a novel concept on how aPC and thrombin mediate distinct effects. We propose that the enzyme specific cleavage sites induce specific conformations which mediate divergent downstream effects. This unexpected model of PAR1 signaling might lead to novel therapeutic options for treatment of inflammatory diseases.